A case control series for the effect of photobiomodulation in patients with low back pain and concurrent depression

Charles Philip Gabel 1, Samuel R Petrie 2, David Mischoulon 2, Michael R Hamblin 3, 4, Albert Yeung 2, Lisa Sangermano 2, Paolo Cassano 2, 5

1: Coolum Physiotherapy, Sunshine Coast, Queensland
2: Harvard Medical School, Depression Clinical and Research Program, Harvard University, Massachusetts General Hospital, Boston
3: Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Department of Dermatology, Harvard Medical School, Boston
4: Harvard-MIT Division of Health Science and Technology, Cambridge MA 02139.
5: Harvard Medical School, Center for Anxiety and Traumatic Stress Disorders, Harvard University, Massachusetts General Hospital, Boston

Background and aims: To present incidental findings in patients with low back pain (LBP) who received photobiomodulation (PBM) administered to the back and thighs as an adjunct to physical therapy (PT) and then experienced improvement in concurrent depression.

Materials and methods: Five outpatients with LBP and concurrent self-reported depression were treated for LBP over five weeks with PT (5-sessions) and concurrent PBM (final 3-sessions), and retrospectively matched to five control patients treated with PT alone (5-sessions). The PBM device emitted light at 850nm and 660 nm with an irradiance of 100 mW/cm² and fluence of 3 J/cm² on 12 symmetrical posterior sites (thoracic, lumbar and thighs) for 30 sec/site.

Results: Both groups had non-significant differences in all baseline scores, except for higher functional status (ARGS) in the PBM-group (33.6 ± 12.2 vs. 18.6 ± 3.6, t(8) = 2.638, p = 0.030). After treatment, the mean decrease in depression scores (OMSQ-12 item #6) was significantly larger in the PBM-group (43.0 ± 22.0 vs. 8.0 ± 5.7, t(8) = 3.449, p = 0.009). Improvement in functional status (ARGS) in the PBM-group was similar to that in the controls (42.0 ± 13.5 vs. 43.4 ± 11.1, t(8) = 0.179, p = 0.862), suggesting group differences in antidepressant effect were independent of functional status improvement.

Conclusions: This preliminary investigation suggests that an antidepressant effect may result from PBM to the back and thighs in patients with LBP and concurrent depression.

Key words: Depression • photobiomodulation • near infrared and red light • low back pain • low level laser therapy

Introduction

Patients with spine-related problems, 1) chronic-pain or chronic orthopedic disease, 2) and particularly low back pain (LBP), 3) frequently suffer with concurrent major depressive disorder (MDD). When pain and depression are comorbid, causality is difficult to ascertain as the chronic LBP may lead to depression, and physical pain is a common symptom of depression. 4) Regardless of causality, comorbid depression is often associated with more intense pain 5) and worsens the prognosis of LBP. 6) Despite the prognostic relevance in LBP, depression is under-recognized by primary care practitioners. 6-8) Consequently, a brief screening for depression in patients complaining of LBP is recommended, but there is controversy as to the minimum number of questions required. 8-10) Furthermore, the use of specific strategies such as a multidisciplinary rehabilitation program—addressing a combination of physical, psychological, social or work-related factors—

Addressee for Correspondence:
Paolo Cassano, MD, PhD
1 Bowdoin Square, 6th Floor
Massachusetts General Hospital
Boston, MA 02114
1-617-643-9622

©2018 JMLI, Tokyo, Japan
did not demonstrate an additional effect on depressive symptoms when compared to physical rehabilitation alone according to a Cochrane review.  

Depression has been linked to a decreased level of mitochondrial respiration in blood platelets. Consequently, blood cells have been proposed as a target for systemic therapy for depression. This theory suggests possible involvement of whole blood in the pathophysiology of depression. Photobiomodulation (PBM)—an FDA-approved treatment for somatic pain—is based on the boosting of ATP production by near infra-red (NIR) or red light (delivered by either a laser or light emitting diode (LED) source) via stimulation of the mitochondrial respiratory chain. In a few published studies, transcranial PBM and laser acupuncture have shown benefit in patients with depression; however, there is currently no literature indicating whether PBM applied to large areas of peripheral skin (as opposed to the head or to small acupuncture and trigger points) improves depression.

This case series presents incidental findings observed in two separate groups of patients with LBP. In the first group, patients with MDD as diagnosed by their General Practitioner (GP) who scored highly for depression severity, received PBM therapy using NIR and red wavelength light from a LED source. In the second group, patients with similar high depression scores but no clinically-ascertained diagnosis of MDD were not treated with PBM. Both groups received standardized physical therapy including a home exercise therapy program. The aim of the study was to retrospectively test whether NIR and red PBM, applied to large areas of skin on the back and thighs, decreased the severity of depression.

**Materials and methods**

**Patient Selection**

By means of retrospective, post-hoc chart reviews, two homogeneous groups of five outpatients each were formed in two separate case series: a treatment group and a control group. The first group was formed by consecutives patients who received PBM [to the back and posterior thighs] as an adjunct therapy after two initial physical therapy (PT) sessions. The second group subjects were selected as matched controls to the first group based on age, gender, presenting symptoms and level of reported depression. All patients in both groups had been receiving PT after presenting with primary LBP of a musculoskeletal source and with self-reported depression. The entry depression severity was at least moderate—except for one pair of subjects who had mild to moderate depression—based on the Orebro Musculoskeletal Screening Questionnaire, OMSQ-12 item #6 with a cut off > 60% (where 100% is the highest degree of depression). This question format and scaling, expressed as a percentage, was comparable to the one-question depression scale used and determined by Reme and to that by Haggman and colleagues. This study proposal was submitted to an Institutional Review Board (IRB), the Partners Human Research Committee (PHRC). The PHRC determined that the study did not meet criteria for human

<table>
<thead>
<tr>
<th>Table 1: Demographics, Functional Status (determined by ARGS score), and Depression (determined by score on item 6 of the OMSQ-12) at different time points throughout the study for both active (NIR) and control (CTRL) group participants.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Condition</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>NIR</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>CTRL</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

(-) CTRL group participants did not receive an assessment at week 2.
subjects research because no identifiable private information was available to the individuals conducting the research and all data was a retrospective analysis of individual cases grouped to form a series. Thus, it was not necessary to subsequently seek and obtain informed consent from the patients who were selected in and analyzed for this study.

The PBM group (group 1) comprised patients who had been diagnosed as clinically depressed and were also taking Selective Serotonin Re-uptake Inhibitor (SSRI) antidepressants as prescribed by their medical practitioner. Each participant stated they had been on an antidepressant regimen for at least 12 months preceding the onset of the episode of LBP. Each patient was treated for pain with PT alone, including manual and exercise therapy, for two sessions over two weeks and subsequently with PT plus PBM for three sessions over three weeks. The therapeutic choice to concurrently add PBM at the third session was based on the patients’ history of concurrent clinical depression, the fact that no change in the depressive symptoms had resulted from the two previous PT only sessions, and in consideration of the reported benefits of PBM on mood, anxiety and pain. The control group (group 2) was selected retrospectively through a post-hoc matching of the participants in group 1 for age, gender, diagnosis of LBP, treatment with PT, and the presence of depression of similar severity, as measured on the OMSQ-12 item #6. Besides the lack of PBM treatment, group 2 differed from group 1 because, although the subjects had the same measured baseline level of depression—as measured on the OMSQ-12 item #6—they had not been diagnosed with MDD by a GP (self-referrals to PT clinic) nor had they been prescribed nor were taking any antidepressant medications. Consequently, the physical therapist only augmented PT with PBM treatment for patients in LBP (group 1) whose comorbid depression was signaled by their antidepressant medication.

Assessment of Depression and of Functional Outcome

Depression was assessed using a one-question depression scale, extracted from the Short Form 12-item version of the Orebro Musculoskeletal Screening Questionnaire (OMSQ-12) (minimal detectable change- MDC = 20%)—an established questionnaire for the assessment of biopsychosocial-risk profile. The question extracted was Question #6, scored on an 11-point Likert Scale anchored from 0 = ‘Not at all’ to 10 = “Extremely” and stated: “During the past 2-3 days, rate how ‘depressed’ or ‘down’ you have felt”. The conversion to a percentage scale was made by multiplying by a factor of 10.

The anatomical region-specific functional outcome was measured using a ‘Cloud’ based decision support software system—Advise Rehab Software (MDC = 5.0%). This system used a Tablet-PC or I-Pad, as an interface with the patient, to collect responses in the following categories: 1) overall perceived functional status; 2) participation in everyday activities or duties; 3) pain; 4) spine functional status (on a 10-item self-reported outcome—PRO); 5) collateral indicators of daily function (5-item patient specific index of self-selected items). The 5-domain scores were integrated by an algorithm that produced a single score from 0 to 100 on functional status, the Advise Rehab Global Scale (ARGS: 0 = Worst possible function, 100 = Maximum or pre-injury function).

For group 1, all measurements were made on three occasions: at baseline, at week two, following the first two PT sessions, and at discharge (week five)—following the three additional manual therapy sessions with the adjunct PBM. For group 2, the same measurements were conducted at baseline and at discharge (week five), after completion of five manual therapy sessions.

Intervention

Manual therapy consisted of spinal mobilization, massage, and the use of home exercises for range of movement, strength and core control. Both groups received a total of five manual therapy sessions. The therapist was a post-graduate Certified Sports Physical Therapist and Manual Diagnostic Therapist-McKenzie (CPG).

The PBM was delivered by the same therapist (CPG) with a Thor-UK:DDII, LED-104 instrument (see Figure 1). This device delivers both red and NIR continuous wave light and comprises an integrated cluster-probe containing LEDs with the following wavelength and individual LED power values, respectively: 660nm (56 probes each emitting 10 mW) and 850 nm (48 probes each emitting 30 mW). The total power was 2 Watts, roughly 75% NIR and 25% red light. The spot-size of the probe totaled 20 cm² (single spot-size1/e² = 0.2 cm²). The treatment window (total area treated) was 240 cm² and included 12 symmetrical bilateral sites (20 cm² per site):

Figure 1: Image of Thor-UK:DDII, LED-104 instrument
eight thoracic and four posterior-thigh sites (see Figure 2). The average irradiance was 100 mW/cm² and fluence was 3 J/cm². The entire PBM session lasted 6 min (30 sec/site for a total of 12 sites); the NIR and red light were delivered over a 14-18 day period for a total of three treatments at direct skin contact. The dose per session was 720 J (60 J/site).

Analyses

Group 1 and 2 were compared post-hoc to determine the effect of PBM on the reported levels of depression as well as on overall functional status. Baseline demographic variables and severity scores were compared between the two groups by independent samples t-test for equality of means and by Fisher’s Exact test, for continuous and dichotomous variables, respectively (2-tailed significance at \( p \leq 0.05 \)). Mean changes in depression scores (OMSQ-12 item #6) and in function (ARGS total score) from baseline to discharge were compared between the two groups by independent samples t-test for equality of means (2-tailed significance at \( p \leq 0.05 \)). A secondary analysis was conducted within the PBM group (1), to compare the mean changes in depression scores, within the same subjects, pre- and post- PBM, by paired samples t-test. For graphic representation only, within each group, the mean total scores for depression and function were compared from baseline to discharge by paired sample t-test. Two-tailed significance for all five secondary analyses was set at \( p \leq 0.01 \) after adopting a Bonferroni correction (SPSS Inc. Released 2008. SPSS Statistics for Windows, Version 17.0. Chicago: SPSS Inc.).

Results

Gender and age were similar for the PBM treatment group and for the matched control group (60% women in both groups; age 60.2 ± 10.2 vs. 58.4 ± 12.5 years) (statistics not shown; \( p \)-value not significant) (see Table 1). The two groups showed identical baseline depression severity (OMSQ-12 item #6 at baseline: 70.0 ± 20.0; Figure 3); however, functional status was significantly worse in the control group (PBM vs. Controls; ARGS total score at baseline 33.6 ± 12.2 vs. 18.6 ± 3.6, \( t(8) = 2.638, p = 0.030 \); Figure 4). All but one subject per group had at least moderate depression severity; the remainder mild to moderate severity.

The change in depression scores from baseline to discharge (after the 5th session) was significantly greater in the PBM group than in the control group (decrease in OMSQ-12 item #6 baseline - endpoint: 43.0 ± 22.0 vs. 8.0 ± 5.7, \( t(8) = 3.449, p = 0.009 \); Figure 3). Notably, both groups im-
proved significantly regarding functional status (Figure 4), and the change in functional status in the PBM group was similar to the change observed in the control group (increase in ARG5 total score baseline - endpoint: 42.0 ± 13.5 vs. 43.4 ± 11.1, t(8) = 0.179, p = 0.862; Figure 4). This suggests that the group differences for the antidepressant effect were independent of improvements in function and pain. See also Figure 3 and 4, depicting the histograms of the mean total scores for depression and function, respectively, at baseline and endpoint.

When a secondary analysis was performed within the PBM treatment group, the change in depression during the actual PBM phase (sessions # 3-5) was significantly greater than the change in depression during pre-PBM phase (sessions # 1-2; change in OMSQ-12 item #6 pre-session #5 -endpoint 33.0 ± 16.0 vs. item #6 baseline - post-session #2 10.0 ± 6.1, t(4) = 4.960, p = 0.008).

Discussion

To our knowledge this is the first study to suggest –based on incidental findings– that PBM delivered to large areas of the skin may exert an antidepressant effect in subjects reporting LBP.

Two small, open studies have shown the antidepressant effect of transcranial PBM (NIR 810 nm and 808 nm) in patients suffering from major depressive disorder: both studies suggested a robust, though non-sustained, response rate to NIR. 20, 17) Additional open studies have also reported an antidepressant and anxiolytic effect in subjects treated with transcranial PBM for traumatic brain injury (TBI). 34-36) The primary mechanism hypothesized to explain the therapeutic effects of transcranial PBM is the boosting of brain metabolism, mediated by direct potentiation of the mitochondrial respiratory chain. 37, 38)

Interestingly, an Australian group has also used laser NIR (808 nm) light, though non-transcranially, delivered to acupuncture-points to treat major depressive disorder. The treatment focused on five primary depression acupoints and the total amount of energy delivered during each session ranged from 3 to 5 J. 38, 39) Although this dose of light was apparently low, the total energy delivered over the skin per session was sufficient to produce significant antidepressant effects in two double-blind trials using up to 12 sessions over eight weeks. A placebo-controlled randomized study from a Turkish group examined the effect of laser (904 nm) light-delivered to at least eleven tender points—in patients suffering from fibromyalgia but not MDD. In this trial, the light delivered to multiple circumscribed skin areas (each of 1 cm²) had a significant effect on subthreshold depressive symptoms despite the use of low fluence (2 J/cm² for a total of 10 sessions over two weeks). 39) These clinical effects might result from PBM of the peripheral and central nervous system, considering that acupoints—and possibly tender points– have been shown to overlap major neuronal bundles. 40)

Our findings suggest that PBM to the skin (NIR 850nm and red 660nm) might indeed exert an antidepressant effect, even when the nervous system is not directly or specifically targeted, as opposed to PBM administered to the skull or to acupoints or tender points. The assumption is that NIR and red light, delivered to large areas of the skin and to the embedded vasculature, might significantly affect systemic processes such as hypometabolism, inflammation, and oxidative stress, implicated in the pathophysiology of depression. 12, 15)

Limitations and Strengths

Our study has several limitations. 1) The use of antidepressant medications in the PBM group is a confounding factor. It is possible, but unlikely, that the antidepressant effect in this latter group was due to the medications and not to the PBM. While we do not have sufficient information on concomitant treatments to rule this out, patients had been on antidepressants for at least 12 months and were still clinically depressed. Moreover, within the PBM group there was a statistically-significant antidepressant benefit reported following the PBM sessions, when compared to the prior phase of only manual PT. 2) The extracted depression measurement questionnaire used in this study has not been separately validated, whereas the original scale has been. However, our screening question for depression is similar in wording and scoring to the question used and validated by Reme and colleagues 9) for patients with LBP and depression, and also to that used by Haggman and colleagues. 6) The single-item screening question used by Reme 9) was extracted from the Subjective Health Complaint Inventory (SHCI) 10) and compared to the Hospital Anxiety and Depression Scale 11) and the Hopkins Symptom Checklist-25 12) and is sensitive to depression severity. 3) Our open, retrospective case-series study is subject to limitations inherent to its design including patients’ expectation that an additional device-based intervention might help them (placebo effect) and including the lack of randomization with a rigorously designed and deployed sham comparison. However, it is unlikely that the psychological benefits reported by the PBM-group were secondary to improvements in physical function and pain, since these latter measurements improved to a similar extent in both groups, with and without PBM. 4) The lack of a documented clinical diagnosis of MDD in the control group might invalidate our comparison. Still, the high comorbidity between LBP and clinical depression and the endorsement of equally severe depressed mood in both study groups suggest that our controls might be adequate.

The primary strength of this case-series is that it reports incidental, clinically-significant findings which were common to all patients receiving PBM. The latter is the single common intervention that might have contributed
to the changes in depression: the use of NIR and red light over a large area of body skin providing potential systemic effects. The results suggest that the PBM sessions might have improved symptoms of depression in five patients; as a statistically significant difference was found both, within the PBM-treated group following the addition of the PBM to the PT regime, and between patients who did and did not received the PBM sessions.

Conclusions

This clinical case-series presents incidental findings on the effects of PBM-therapy on problematic LBP patients with concurrent depression. The use of PBM to large areas of the skin might have beneficial effects as part of a multi-modal treatment approach specifically targeted to depressed patients. However, in this case-series report, PBM cannot be identified as the single-agent producing the psychological benefit, due to the above limitations in the design, and the findings must therefore be considered preliminary. Prospective randomized controlled trials are necessary to better characterize the efficacy of PBM in the population of our study.

References


Gabel CP et al.

Acknowledgments
We would like to acknowledge the Brain & Behavior Research Foundation for providing salary support for Dr. Cassano (NARSAD Young Investigator Award). The sponsor was not involved in data collection and analysis or manuscript preparation and submission.